And the winner is ….

And the winner is ….

This Sunday the New England Patriots and Atlanta Falcons will face off in Superbowl LI with millions around the global watching. When it comes to the diabetes drug sector Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are battling it out for supremacy and right now Lilly is winning. Something which was reinforced as both reported 4th quarter and full year results this week. As it stands today Lilly is playing all facets of the game while Novo continues to struggle a little. As we have noted several times Lilly has the most comprehensive portfolio of diabetes therapies and has . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.